R&D Meets The Crowdscape: BioMed X Looks Outside For Insight
An extended inter-disciplinary approach to preclinical research may offer the best leads against today’s biggest challenges in medicine.
It is a cliché to say that pharma science loves to collaborate – the hard thing is that leaky decision framework by which good ideas do not get executed.
You may also be interested in...
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.